Answers are grounded in this paper and cite their sources.
Preclinical study reveals aged hepatocyte CD44 activates IL-6/STAT3 signaling and impairs neighboring T cells, indicating an immunosuppressive mechanism behind age-related liver cancer.
Liver cancer incidences increase dramatically beyond 55 years of age, suggesting that age-associated changes contribute critically to tumor initiation. However, the mechanisms linking liver aging and cancer initiation remain incompletely defined. This study investigated the role of CD44, a marker of liver tumor-initiating cells (TICs), in age-associated liver pathophysiology. To define the role of CD44 in aged livers, we profiled CD44-expressing hepatocytes in young and aged livers by targeted and unbiased -omics methods, assessed their number and relationship to neighboring T cells by spatial transcriptomics, and validated key findings using hepatocyte-specific Cd44 knockout. Aged livers showed an accumulation of CD44-expressing hepatocytes enriched for immune modulatory genes and activation of the immunosuppressive IL-6/JAK/STAT3 pathway. Consistent with an immunosuppressive aged milieu, following their adoptive transfer antigen-exposed CD8+ T cells mounted a lower IFN-γ response in aged livers than in young livers. Concordantly, spatial analyses showed that neighborhoods proximal to Cd44 -expressing hepatocytes are enriched in T cells exhibiting reduced cytokine and chemokine gene expression. Finally, hepatocyte-specific knockout of Cd44 mitigated the IL-6/JAK/STAT3 gene signature in aged livers. Overall, these findings suggest that CD44 expression in aged hepatocytes promotes activation of the immunosuppressive IL-6/JAK/STAT3 pathway associated with impaired T cell effector function, potentially, contributing to the increased incidence of liver cancer with age.
No takes yet. Share an insight, caveat, or question.
Gandhi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: